News

Medtronic (NYSE: MDT) is a stock I bought and have added to several times. I'm not a healthcare-focused investor, but the stock's historically high 3.6% dividend yield and long history of annual

Weight-loss drugs present an enormous opportunity in the healthcare market. Wegovy and Mounjaro are some of the top-selling drugs available in that indication, and companies that make them -- Novo

You don't need a lot of money to get going in the market these days. The growing popularity of zero-commission trading means that even $20 is more than enough to buy a piece of a potentially

Shares of telecom giant AT&T (NYSE: T) have been stuck in a rut for much of 2023. Slowing subscriber growth, an uncertain economic outlook, mountains of debt, and fear that the company's free cash

Medical-devices company Medtronic's (NYSE: MDT) stock was in good health on Tuesday. Following the company's release of its latest set of quarterly figures, investors traded it up by nearly 5%. That

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q2 2024 Earnings CallNov 21, 2023, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

A dividend yield can tell you a lot about a payout. Not only does it tell you how much you could be collecting in dividend income, but it can give you an indication of investor sentiment, and

Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to

The Federal Reserve (Fed) is the central bank of the U.S., responsible for regulating banks, implementing monetary policy, and maintaining the financial system's stability. One aspect of the latter

Dividend stocks offer many potential benefits to investors. They can provide income, boost returns through dividend reinvestment plans, act as a hedge against inflation and economic downturns, and

Last year, tech giant Amazon (NASDAQ: AMZN) and medical device specialist DexCom (NASDAQ: DXCM) were among the several high-profile companies to conduct stock splits. This move attracted plenty of

All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting

When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity

Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time.

Which smaller stocks

The biotech company that's able to deliver the next game-changing treatment might become tomorrow's winner -- and offer your portfolio a giant boost.

Problem is, it's not always easy to identify

Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.

There's a good reason for this

With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But

U.K.-based AstraZeneca (NASDAQ: AZN) is now gearing up for the second time to develop a challenger to Novo Nordisk's (NYSE: NVO) Ozempic, its absurdly successful treatment for type 2 diabetes. If

Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader